• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    2/11/26 4:08:44 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EIKN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Eikon Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    282564103

    (CUSIP Number)


    02/04/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Fund IV, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,960,774.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,960,774.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,960,774.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row 5: 1,960,774 shares, except that Foresite Capital Management IV, LLC ("FCM IV"), the general partner of Foresite Capital Fund IV, L.P. ("FCF IV"), may be deemed to have sole power to vote these shares, and James Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 1,960,774 shares, except that FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of Eikon Therapeutics, Inc. (the "Issuer") as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Management IV, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,960,774.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,960,774.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,960,774.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: 1,960,774 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 1,960,774 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Fund V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,353,168.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,353,168.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,353,168.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.5 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row 5: 1,353,168 shares, except that Foresite Capital Management V, LLC ("FCM V"), the general partner of Foresite Capital Fund V, L.P. ("FCF V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 1,353,168 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Management V, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,353,168.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,353,168.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,353,168.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.5 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: 1,353,168 shares, all of which are directly owned by FCF V. FCM V, the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 1,353,168 shares, all of which are directly owned by FCF V. FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Opportunity Fund V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    425,852.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    425,852.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    425,852.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Note to Row 5: 425,852 shares, except that Foresite Capital Opportunity Management V, LLC ("FCM Opp V"), the general partner of Foresite Capital Opportunity Fund V, L.P. ("FCF Opp V"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 425,852 shares, except that FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital Opportunity Management V, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    425,852.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    425,852.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    425,852.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: 425,852 shares, all of which are directly owned by FCF Opp V. FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 425,852 shares, all of which are directly owned by FCF Opp V. FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital VI-A, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    408,725.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    408,725.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    408,725.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: 408,725 shares, except that Foresite Capital VI-A Management, LLC ("FCM VI-A"), the managing member of Foresite Capital VI-A, LLC ("FC VI-A"), may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FC VI-A, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 408,725 shares, except that FCM VI-A, the managing member of FC VI-A, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI-A, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Foresite Capital VI-A Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    408,725.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    408,725.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    408,725.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Note to Row 5: 408,725 shares, all of which are directly owned by FC VI-A. FCM VI-A, the managing member of FC VI-A, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM VI-A, may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 408,725 shares, all of which are directly owned by FC VI-A. FCM VI-A, the managing member of FC VI-A, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM VI-A, may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    James B. Tananbaum
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,148,519.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,148,519.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,148,519.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Note to Row 5: 4,148,519 shares, of which 1,960,774 shares are directly owned by FCF IV, 1,353,168 shares are directly owned by FCF V, 425,852 shares are directly owned by FCF Opp V and 408,725 shares are directly owned by FC VI-A. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V, FCM Opp V, which is the general partner of FCF Opp V and FCM VI-A, which is the managing member of FC VI-A. Tananbaum may be deemed to have sole power to vote these shares. Note to Row 6: See response to Row 5. Note to Row 7: 4,148,519 shares, of which 1,960,774 shares are directly owned by FCF IV, 1,353,168 shares are directly owned by FCF V, 425,852 shares are directly owned by FCF Opp V and 408,725 shares are directly owned by FC VI-A. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V, FCM Opp V, which is the general partner of FCF Opp V and FCM VI-A, which is the managing member of FC VI-A. Tananbaum may be deemed to have sole power to dispose of these shares. Note to Row 8: See response to Row 7. Note to Row 11: This percentage is calculated based upon 53,984,337 Common Stock outstanding of the Issuer as of February 4, 2026, as set forth in the Issuer's 424B4 filed with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Eikon Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    230 Harriet Tubman Way, Millbrae, CA 94030
    Item 2. 
    (a)Name of person filing:

    This Schedule is filed by Foresite Capital Fund IV, L.P., a Delaware limited partnership, Foresite Capital Management IV, LLC, a Delaware limited liability company, Foresite Capital Fund V, L.P., a Delaware limited partnership, Foresite Capital Management V, LLC, a Delaware limited liability company, Foresite Capital Opportunity Fund V, L.P., a Delaware limited partnership, Foresite Capital Opportunity Management V, LLC, a Delaware limited liability company, Foresite Capital VI-A, LLC, a Delaware limited liability company, Foresite Capital VI-A Management, LLC, a Delaware limited liability company and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    c/o Foresite Capital Management 9200 W. Sunset Boulevard, Suite 515 West Hollywood, CA 90069
    (c)Citizenship:

    See Row 4 of cover page for each Reporting Person.
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    282564103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.
    (b)Percent of class:

    See Row 11 of cover page for each Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreements of FCF IV, FCF V and FCF Opp V and the limited liability company agreements of FC VI-A, FCM VI-A, FCM IV, FCM V and FCM Opp V, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Foresite Capital Fund IV, L.P.
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member of the General Partner
    Date:02/11/2026
     
    Foresite Capital Management IV, LLC
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member
    Date:02/11/2026
     
    Foresite Capital Fund V, L.P.
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member of the General Partner
    Date:02/11/2026
     
    Foresite Capital Management V, LLC
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member
    Date:02/11/2026
     
    Foresite Capital Opportunity Fund V, L.P.
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member of the General Partner
    Date:02/11/2026
     
    Foresite Capital Opportunity Management V, LLC
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member
    Date:02/11/2026
     
    Foresite Capital VI-A, LLC
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member of the Managing Member
    Date:02/11/2026
     
    Foresite Capital VI-A Management, LLC
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum, Managing Member
    Date:02/11/2026
     
    James B. Tananbaum
     
    Signature:/s/ James Tananbaum
    Name/Title:James Tananbaum
    Date:02/11/2026
    Exhibit Information

    Exhibit A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Date: February 11, 2026 FORESITE CAPITAL FUND IV, L.P. By: FORESITE CAPITAL MANAGEMENT IV, LLC Its: General Partner By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL MANAGEMENT IV, LLC By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL FUND V, L.P. By: FORESITE CAPITAL MANAGEMENT V, LLC Its: General Partner By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL MANAGEMENT V, LLC By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL OPPORTUNITY FUND V, L.P. By: FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC Its: Managing Member By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL VI-A, LLC By: FORESITE CAPITAL VI-A MANAGEMENT, LLC Its: Managing Member By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member FORESITE CAPITAL VI-A MANAGEMENT, LLC By: /s/ James Tananbaum Name: James Tananbaum Title: Managing Member JAMES TANANBAUM By: /s/ James Tananbaum Name: James Tananbaum

    Get the next $EIKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EIKN

    DatePrice TargetRatingAnalyst
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$32.00Overweight
    Morgan Stanley
    3/2/2026$29.00Overweight
    Analyst
    3/2/2026$26.00Outperform
    Mizuho
    3/2/2026$34.00Buy
    BofA Securities
    2/26/2026$7.00Underperform
    Wedbush
    More analyst ratings

    $EIKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eikon Therapeutics

    Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight

    3/2/26 9:11:04 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Eikon Therapeutics with a new price target

    Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00

    3/2/26 9:06:14 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Eikon Therapeutics with a new price target

    Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00

    3/2/26 9:05:58 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/18/26 4:16:58 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.

    SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/12/26 6:48:54 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/11/26 4:08:44 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Klobuchar Michael A

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:04:29 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:02:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Frazier Kenneth C

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:01:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iv Gp, Lp converted options into 3,595,340 shares and bought $38,119,680 worth of shares (2,117,760 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/9/26 9:19:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 7:37:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frazier Kenneth C bought $1,999,998 worth of shares (111,111 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 6:33:01 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care